Loading…
Loading…
EQUITY / NASDAQ · XNMS
Liminatus Pharma, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗3.9 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 3.9 USD · Volume 24,346
358 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -1,378,908 USD | -1,118,211 USD | — |
| Net income | -1,407,259 USD | 113,287 USD | -1,342.21% |
| Total liabilities | 3,103,090 USD | — | — |
| Total equity | 300,612 USD | -8,807,412 USD | — |
| Total assets | 3,403,702 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Net incomeIncome statement | -1,407,259 USD | -2,530,973 USD | -1,123,714 USD | — | -10,206,517 USD | -1,823,351 USD | -2,037,590 USD | 113,287 USD |
| Operating profitIncome statement | -1,378,908 USD | -2,479,806 USD | — | — | -2,967,812 USD | -701,170 USD | -2,083,601 USD | -1,118,211 USD |
| Total assetsBalance sheet | 3,403,702 USD | — | — | 512,795 USD | 512,795 USD | 1,342,409 USD | — | — |
| Total equityBalance sheet | 300,612 USD | — | -132,596 USD | -9,814,690 USD | -9,814,690 USD | -1,645,763 USD | — | -8,807,412 USD |
| Total liabilitiesBalance sheet | 3,103,090 USD | — | — | 10,327,485 USD | 10,327,485 USD | 2,988,172 USD | — | — |
| Financing cash flowCash flow statement | — | 5,664,729 USD | — | — | 11,032,762 USD | — | 11,032,762 USD | — |
| Operating cash flowCash flow statement | — | -2,985,288 USD | — | — | -9,963,318 USD | — | -9,576,471 USD | — |
| Capital expendituresCash flow statement | — | — | — | — | 13,108 USD | — | 13,108 USD | — |
| Investing cash flowCash flow statement | — | — | — | — | -788,108 USD | — | -788,108 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/31/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.